Relugolix Clinical Trials
11 actively recruiting trials across 9 locations
Also known as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385, TAK385, medroxyprogesterone acetate, megestrol acetate
Phoenix, Arizona2 trials
Cancer Center at Saint Joseph's
Other1 trial
Birmingham, Alabama1 trial
University of Alabama at Birmingham Cancer Center
Anchorage, Alaska1 trial
Anchorage Associates in Radiation Medicine
Scottsdale, Arizona1 trial
Orlando, Florida1 trial
AdventHealth Orlando
Atlanta, Georgia1 trial
Emory Proton Therapy Center
Chicago, Illinois1 trial
Boston, Massachusetts1 trial
Brigham and Women's Hospital
Columbus, Ohio1 trial
Ohio State University Comprehensive Cancer Center
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.